TY - JOUR
T1 - Correction to
T2 - Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer (Breast Cancer Research and Treatment, (2019), 175, 2, (339-351), 10.1007/s10549-019-05166-3)
AU - Lee, Jangsoon
AU - Lim, Bora
AU - Pearson, Troy
AU - Choi, Kuicheon
AU - Fuson, Jon A.
AU - Bartholomeusz, Chandra
AU - Paradiso, Linda J.
AU - Myers, Thomas
AU - Tripathy, Debu
AU - Ueno, Naoto T.
N1 - Funding Information:
Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.” The first affiliations was incorrect in the original article. The correct information is given below.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/7/15
Y1 - 2019/7/15
N2 - Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.” The first affiliations was incorrect in the original article. The correct information is given below.
AB - Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.” The first affiliations was incorrect in the original article. The correct information is given below.
UR - http://www.scopus.com/inward/record.url?scp=85064336631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064336631&partnerID=8YFLogxK
U2 - 10.1007/s10549-019-05218-8
DO - 10.1007/s10549-019-05218-8
M3 - Comment/debate
C2 - 30982934
AN - SCOPUS:85064336631
SN - 0167-6806
VL - 176
SP - 251
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -